Shanghai Medicilon, Inc. Class A

As of June 30, 2026, Shanghai Medicilon, Inc. Class A carries a market capitalization of 10.84B, placing it among publicly traded companies globally. Its enterprise value stands at 10.58B, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

Shanghai Medicilon, Inc. Class A's next confirmed earnings release is scheduled for October 30, 2026.

As of June 30, 2026, Shanghai Medicilon, Inc. Class A has 134.35M shares outstanding.

These figures are as of June 30, 2026. The price-to-sales ratio is 7.84, and the price-to-book ratio stands at 5.41.

These figures are as of June 30, 2026. The EV/Sales ratio of 7.81 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 10.58B versus a market cap of 10.84B, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2026, Shanghai Medicilon, Inc. Class A maintains a current ratio of 1.84, meaning it holds 1.8x the short-term assets needed to cover near-term liabilities. The debt-to-equity ratio is 11.12, indicating elevated leverage, while an interest coverage ratio of -9.43 demonstrates limited ability to service its debt obligations.

Over the twelve months ended June 30, 2026, Shanghai Medicilon, Inc. Class A posted a negative return on equity (ROE) of -4.11, meaning shareholder capital produced losses rather than profits. Return on assets (ROA) is negative at -2.97, reflecting losses generated across the asset base. The company generates approximately 549,594.46 in revenue per employee across its workforce of 2,465.25, a quick read on workforce productivity versus industry peers. Inventory turnover of 7.07 indicates how many times Shanghai Medicilon, Inc. Class A sells and replaces its inventory over a year, a key working capital efficiency ratio.

Over the twelve months ended June 30, 2026, Shanghai Medicilon, Inc. Class A recorded an income tax benefit of -5.75M rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -90.65M and -84.89M in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Shanghai Medicilon, Inc. Class A's stock has gained approximately 24.02% over the past 52 weeks. The 50-day moving average sits at 98.72, while the 200-day moving average is 74.38.

Over the twelve months ended June 30, 2026, Shanghai Medicilon, Inc. Class A generated 1.35B in revenue and converted that into -84.89M in net income, yielding earnings per share of -0.65. EBITDA reached -77.85M, while operating income came in at 11.22M.

As of June 30, 2026, Shanghai Medicilon, Inc. Class A holds 481.37M in cash and equivalents against 222.71M in total debt, resulting in a net debt position of -131.80M. Total book value stands at 2.00B, with working capital of 653.23M providing operational flexibility.

These figures cover the twelve months ended June 30, 2026.

Over the twelve months ended June 30, 2026, Shanghai Medicilon, Inc. Class A posted a gross margin of 24.13, reflecting its pricing power and cost economics. The operating margin of 0.83 and net profit margin of -6.27 provide insight into operational efficiency.

Over the twelve months ended June 30, 2026, Shanghai Medicilon, Inc. Class A paid dividends of 0.05 per share. The dividend payout ratio of -7.14 is negative because earnings are negative, so the dividend is being paid out of something other than profits, a key gauge of how sustainable the dividend is and how much room remains for future dividend growth. Total shareholder yield reaches 1.76, combining dividends paid with share buybacks and debt reduction for a fuller picture of capital returned to Shanghai Medicilon, Inc. Class A shareholders.

Shanghai Medicilon, Inc. Class A's most recent stock split took place on June 2, 2023 with a 5:7 split ratio.

As of June 30, 2026, Shanghai Medicilon, Inc. Class A has an Altman Z-Score of 8.37, well above the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.